Xarelto® on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study.

Trial Profile

Xarelto® on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Embolism; Stroke
  • Focus Adverse reactions
  • Acronyms XASSURE
  • Sponsors Bayer
  • Most Recent Events

    • 07 Jun 2017 Planned End Date changed from 30 May 2020 to 30 Aug 2021.
    • 07 Jun 2017 Planned primary completion date changed from 30 Apr 2020 to 30 Jun 2021.
    • 17 Aug 2016 Planned End Date changed from 1 Jul 2018 to 1 May 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top